Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin

Fig. 4

Circ_0000098 promotes HCC development and P-gp expression via the miR-383/MCUR1 axis. A-D Flow cytometry analysis (A), clone formation assays (B), migration assays (C), and invasion assays (D) were conducted to detect cell cycle arrest in the indicated cells. E–F Detection of ATP levels in HCC-LM3 (E) and BEL-7404 (F) cells transfected as indicated. G-H RT-qPCR assays were used to detect P-gp expression in HCC-LM3 (G) and BEL-7404 (H) cells transfected as indicated. I-J Detection of ATP levels in HCC-LM3 (I) and BEL-7404 (J) cells transfected as indicated. K-L RT-qPCR assays were used to detect P-gp expression in HCC-LM3 (K) and BEL-7404 (L) cells transfected as indicated. M Detection of P-gp protein expression in sh-1- and sh-NC-transfected HCC-LM3 cells using western blotting analysis (N) The effect of circ_0000098 on extracellular DOX resistance in HCC was detected by CCK-8 assay (O) The expression of circ_0000098 in DOX-resistant patients. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page